Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.
Press releases published on May 13, 2025
First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
GlobeNewswire
·
May 13, 2025
- ATTRibute-CM, BridgeBio’s Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or first CVH versus placebo in ATTRv-CM patients (59.1% risk reduction), establishing the mechanistic …
XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements
GlobeNewswire
·
May 13, 2025
Pipeline advancements: The Marketing Authorization Application (MAA) for Day One Biopharmaceuticals and Ipsen’s tovorafenib was accepted for review by the European Marketing Authority (EMA) and Takeda initiated its Phase 3 trial exploring mezagitamab for …
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates
GlobeNewswire
·
May 13, 2025
BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates …
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting
GlobeNewswire
·
May 13, 2025
In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene …
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
GlobeNewswire
·
May 13, 2025
- In a Phase 1 study, EMP-01 (oral R-MDMA) demonstrated a unique, dose-dependent subjective effect profile that was generally found to be more similar to classical psychedelics than to racemic MDMA - The exploratory, randomized, double-blind, placebo- …
Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights
GlobeNewswire
·
May 13, 2025
Treated first FTD-GRN patient with Dose 2 PBFT02 and enrolled second patient; several additional patients being evaluated for trial eligibility Announced presentation of process development data of a high productivity, suspension-based manufacturing …
Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference
GlobeNewswire
·
May 13, 2025
SAN FRANCISCO and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its …
Microbix & Aurevia Introduce Novel EQA Scheme
GlobeNewswire
·
May 13, 2025
MISSISSAUGA, Ontario and HELSINKI, Finland, May 13, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and Aurevia Oy via its Labquality EQAS affiliate (Aurevia), …
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital
GlobeNewswire
·
May 13, 2025
GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has entered into …
GenVivo Highlights GEN2 Phase 1 Data and GEN-1013 Preclinical Data at the 2025 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting
GlobeNewswire
·
May 13, 2025
GEN2 is well tolerated with minimal toxicity and signs of pharmacodynamic activity in an ongoing Phase 1 dose escalation and expansion trial. GEN-1013 was studied in aggressive murine cancer models using both IV and IT administration; prolonged survival, …
DIGITAL LANDIA, LLC IN COOPERATION WITH PETVIVO HOLDINGS, INC. UNVEILS REVOLUTIONARY AUTONOMOUS PET AI ECOSYSTEM TRANSFORMING PET CARE WITH SELF-LEARNING MULTI-AGENT AI TECHNOLOGY
GlobeNewswire
·
May 13, 2025
MIAMI, FL, May 13, 2025 (GLOBE NEWSWIRE) -- Digital Landia, LLC, in cooperation with PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) and its wholly owned subsidiary PetVivo Animal Health, Inc. (collectively referred to herein as "PetVivo"), today …
Arbor Biotechnologies to Present Preclinical Data for ABO-101 in PH1 at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
GlobeNewswire
·
May 13, 2025
– Data from oral presentation supported ABO-101 IND and CTA approval for clinical assessment in primary hyperoxaluria type 1 (PH1) in the Phase 1/2 redePHine study in US and UK (NCT06839235) – Preclinical data demonstrate highly specific and durable …
NewBiologix Presents New Data at ASGCT on the Effective Manufacturing of rAAV-based therapeutics
GlobeNewswire
·
May 13, 2025
LAUSANNE, Switzerland, May 13, 2025 (GLOBE NEWSWIRE) -- NewBiologix, a next-generation biotechnology company pioneering the future of recombinant adeno-associated virus (rAAV) production through a unique DNA-based platform built on stable cell line …
TILT Biotherapeutics Announces Closing of USD 25 Million Series B Financing
GlobeNewswire
·
May 13, 2025
HELSINKI, May 13, 2025 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (Tiltbio), a clinical-stage biotechnology company developing intravenously delivered cancer immunotherapies, announces it has raised USD 25.6 million (EUR 22.6 million) in a Series B financing …
Eleva Appoints Donato Spota as Chief Financial Officer
GlobeNewswire
·
May 13, 2025
Freiburg im Breisgau, Germany, May 13, 2025 – Eleva, a pioneer in discovering and developing previously inaccessible biologics based on a breakthrough technology platform, appointed Mr. Donato Spota as Chief Financial Officer (CFO) and Managing Director. …
EG 427 présente à l’ASGCT des avancées majeures réalisées avec sa plateforme HERMES en neurologie, démontrant la polyvalence de ses vecteurs herpétiques non-réplicatifs
GlobeNewswire
·
May 13, 2025
Les données montrent les avantages d'un vecteur HSV-1 non réplicatif (nrHSV-1) unique intégrant deux transgènes présentant des cinétiques d'expression indépendantes. Ces vecteurs transduisent efficacement les neurones du SNC à de très faibles doses et …
Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes
GlobeNewswire
·
May 13, 2025
Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments Galapagos to explore all strategic alternatives for its existing businesses, including cell therapy, with a focus on maximizing …
NMD Pharma to present compelling preclinical data highlighting the potential of ClC-1 ion channel inhibition to improve disease symptoms and progression in MuSK myasthenia gravis at the MGFA International Conference on Myasthenia and Relate
GlobeNewswire
·
May 13, 2025
NMD Pharma to present compelling preclinical data highlighting the potential of ClC-1 ion channel inhibition to improve disease symptoms and progression in MuSK myasthenia gravis at the MGFA International Conference on Myasthenia and Related Disorders The …
Arialief Reviews and Complaints 2025: What Science Says About This Neuropathy Relief Supplement (EXPOSED)
GlobeNewswire
·
May 13, 2025
FINDLAY, Ohio, May 13, 2025 (GLOBE NEWSWIRE) -- For years, I've explored every avenue for neuropathy relief—countless supplements, treatments promising quick fixes, and prescriptions that often left me disappointed. When I first encountered Arialief, a …
Coastland Dental Introduces Advanced Dental Technology to Enhance Patient Experiences in Burbank
GlobeNewswire
·
May 13, 2025
Burbank, CA, May 12, 2025 (GLOBE NEWSWIRE) -- Coastland Dental, a leading dental practice in Burbank, is introducing advanced dental technologies to make dental care more comfortable, efficient, and personalized for patients. By integrating iTero scanning, …